• OPEN AN ACCOUNT
Indian Indices
Nifty
24,631.30 11.95
(0.05%)
Sensex
80,597.66 57.75
( 0.07%)
Bank Nifty
55,341.85 160.40
( 0.29%)
Nifty IT
34,833.20 140.25
( 0.40%)
Global Indices
Nasdaq
44,924.55 -18.73
(-0.04%)
Dow Jones
6,489.27 1.69
(0.03%)
Hang Seng
43,330.92 681.66
(1.60%)
Nikkei 225
9,177.24 12.01
(0.13%)
Forex
USD-INR
87.51 -0.12
(-0.14%)
EUR-INR
102.40 0.39
(0.38%)
GBP-INR
118.57 0.53
(0.45%)
JPY-INR
0.59 0.00
(0.27%)

EQUITY - MARKET SCREENER

Dishman Carbogen Amcis Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
540701
INE385W01011
257.0734185
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DCAL
0
4197.87
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Lupin partners with Sandoz for launch and commercialization of ranibizumab across global markets
Aug 12,2025

Lupin today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions.

Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV).